Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study.

MLA

Nagane, Motoo, et al. “Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study.” Cancers, vol. 14, no. 22, Nov. 2022, p. 5522. EBSCOhost, https://doi.org/10.3390/cancers14225522.

APA

Nagane, M., Ichimura, K., Onuki, R., Narushima, D., Honda-Kitahara, M., Satomi, K., Tomiyama, A., Arai, Y., Shibata, T., Narita, Y., Uzuka, T., Nakamura, H., Nakada, M., Arakawa, Y., Ohnishi, T., Mukasa, A., Tanaka, S., Wakabayashi, T., Aoki, T., & Aoki, S. (2022). Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study. Cancers, 14(22), 5522. https://doi.org/10.3390/cancers14225522

Chicago

Nagane, Motoo, Koichi Ichimura, Ritsuko Onuki, Daichi Narushima, Mai Honda-Kitahara, Kaishi Satomi, Arata Tomiyama, et al. 2022. “Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study.” Cancers 14 (22): 5522. doi:10.3390/cancers14225522.